Secondary Lymphedema Segment to Dominate North America Lymphedema Treatment Market during 2021–2028

According to a new market research study on “North America Lymphedema Treatment Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Condition Type, Treatment Type and End-User” is expected to reach US$ 5,419.77 million by 2028 from US$ 3,880.04 million in 2021. The market is estimated to grow at a CAGR of 4.9% from 2021 to 2028. The report provides trends prevailing in the North America lymphedema treatment market along with the drivers and restraints pertaining to the market growth. Increase in incidence of lymphedema cases is the major factor driving the growth of the North America lymphedema treatment market. However, issues associated with the lack of awareness and skilled professionals hinder the growth of North America lymphedema treatment market.  

The North America lymphedema treatment market is segmented into condition type, treatment type, end-user and country. Based on type, the North America lymphedema treatment market is segmented into primary lymphedema and secondary lymphedema. The secondary lymphedema segment dominated the market in 2020 and primary lymphedema is expected to be the fastest growing during the forecast period. Based on treatment type, the North America lymphedema treatment market is segmented into laser therapy, compression devices and bandaging, drug therapy, physiological procedures, debulking procedures, and others. The compression devices and bandaging segment dominated the market in 2020 and debulking procedures segment is expected to be the fastest growing during the forecast period. Further physiological procedures segment is bifurcated into lymphovenous anastomosis (LVA) and vascularised lymph node transfer (VLNT).Based on end-user, the North America lymphedema treatment market is segmented into hospitals, clinics, clinical research organizations, and others. The hospitals segment dominated the market in 2020 and clinics is expected to be the fastest growing during the forecast period. Based on country, North America lymphedema treatment market is classified into US, Canada, and Mexico.

The world has watched several viruses such as SARS, H1N1, and others over the past few years. However, the severity of the coronavirus made the condition difficult. Coronavirus disease (COVID-19) is a contagious disease that has been affected by a newly discovered coronavirus. In the North American region, the United States was heavily impacted by the outbreak of the COVID-19 pandemic. The country has had the highest number of positive patients. COVID-19, first discovered in December in Wuhan, China, has made more than 203,456,777 people sick worldwide and killed at least 4.3 million people, according to Worldometer data as of August 9th, 2021. US coronavirus cases are increasing the most in the world. There have been around 36,543,338 confirmed cases of COVID-19 in the United States, with 633,116 deaths. The COVID-19 pandemic has brought about technological changes that are critical to better care. As the number of coronavirus cases climbs in the United States, many aspects of quarantine are becoming semi-permanent, at the very least. The prolonged shut-in situation is devastating news for countless industries impacted by business closures, but there are bright spots for sectors that have thrived amid the global health crisis so far. Lymphedema Treatment is one sector that has showed remarkable stamina. According to Marry Ann Libert, the COVID-19 lockdown had a great impact on lymphedema patients in both medical and psychological aspects across the United States.

3M Company, Bio Compression Systems Inc., BSN medical GmbH, Huntleigh Healthcare Limited, Lohmann & Rauscher GmbH & Co. KG, Mego Afek ltd, Sigvaris Group, Smith & Nephew, Tactile Medical, and ThermoTek are among the leading companies in the North America lymphedema treatment market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in 2021, Mego Afek ltd. has announced preliminary data for Lympha Press PCD-51 to be used in chronic venous stasis ulcers.

North America Lymphedema Treatment Market, By Country, 2020 and 2028 (%)

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com